Mutual of America Capital Management LLC Has $3.76 Million Holdings in Envista Holdings Co. (NYSE:NVST)

Mutual of America Capital Management LLC lessened its position in Envista Holdings Co. (NYSE:NVST) by 1.5% in the fourth quarter, HoldingsChannel reports. The fund owned 194,691 shares of the company’s stock after selling 3,060 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Envista were worth $3,756,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in NVST. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Envista during the third quarter valued at approximately $31,000. Huntington National Bank boosted its position in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after buying an additional 538 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the fourth quarter valued at approximately $53,000.

Envista Stock Performance

Shares of NVST opened at $18.28 on Thursday. The firm has a market cap of $3.15 billion, a PE ratio of -2.82, a PEG ratio of 1.27 and a beta of 1.33. The stock’s fifty day moving average price is $20.27 and its two-hundred day moving average price is $19.69. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $23.00.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts forecast that Envista Holdings Co. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Jefferies Financial Group lifted their target price on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Piper Sandler lifted their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Tuesday, February 25th. Morgan Stanley lifted their price target on Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company lifted their price target on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.21.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.